Safety and BNT162b2 mRNA COVID-19 vaccination.
Acta bio-medica : Atenei Parmensis, 2021 n/a.
Joob, Beuy, Wiwanitkit, Viroj
openaire +2 more sources
Annals of the Rheumatic Diseases, 2021 Introduction Vaccination represents a cornerstone in mastering the COVID-19 pandemic. Data on immunogenicity and safety of messenger RNA (mRNA) vaccines in patients with autoimmune inflammatory rheumatic diseases (AIIRD) are limited.
V. Furer +28 more
semanticscholar +1 more source
COVID-19 vaccine in the Kingdom of Saudi Arabia: A true operation warp speed
Journal of Nature and Science of Medicine, 2021 As of January 2021, 1 year has passed since the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was first discovered, which is the cause of the coronavirus disease-2019 (COVID-19) pandemic that has infected almost 100 million people ...
Mazin Barry, Ahmed S BaHammam
doaj +1 more source
Humoral response to mRNA vaccines against SARS-CoV-2 in patients with humoral immunodeficiency disease. [PDF]
, 2022 OBJECTIVES Although mRNA-based vaccines against SARS-CoV-2 induce a robust immune response and prevent infections and hospitalizations, there are limited data on the antibody response in individuals with humoral immunodeficiency. The aim of this study
Bitzenhofer, Michaela +9 more
core +1 more source
Extended interval BNT162b2 vaccination enhances peak antibody generation [PDF]
npj Vaccines, 2022 Abstract The BNT162b2 vaccine is highly effective against COVID-19 infection and was delivered with a 3-week time interval in registration studies 1 . However, many countries extended this interval to accelerate population coverage with a single vaccine.
Helen Parry +9 more
openaire +3 more sources
Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera
Science, 2021 Vaccine protects against B1.1.7 variant The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B1.1.7 (VOC 202012/01) variant that emerged in late 2020 in the United Kingdom has many changes in the spike protein gene.
A. Muik +11 more
semanticscholar +1 more source
Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
medRxiv, 2021 BACKGROUND: Waning of vaccine protection against SARS-CoV-2 infection or COVID-19 disease is a concern. This study investigated persistence of BNT162b2 (Pfizer-BioNTech) vaccine effectiveness against infection and disease in Qatar, where the Beta and ...
H. Chemaitelly +23 more
semanticscholar +1 more source
Herpes zoster related hospitalization after inactivated (CoronaVac) and mRNA (BNT162b2) SARS-CoV-2 vaccination: A self-controlled case series and nested case-control study [PDF]
, 2022 BACKGROUND: Stimulation of immunity by vaccination may elicit adverse events. There is currently inconclusive evidence on the relationship between herpes zoster related hospitalization and COVID-19 vaccination.
Ashcroft, Darren M +19 more
core +1 more source
Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel
New England Journal of Medicine, 2021 Background Approximately 5.1 million Israelis had been fully immunized against coronavirus disease 2019 (Covid-19) after receiving two doses of the BNT162b2 messenger RNA vaccine (Pfizer–BioNTech) by May 31, 2021.
D. Mevorach +26 more
semanticscholar +1 more source
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial [PDF]
, 2022 BACKGROUND: Some high-income countries have deployed fourth doses of COVID-19 vaccines, but the clinical need, effectiveness, timing, and dose of a fourth dose remain uncertain.
Aley, Parvinder K +55 more
core +4 more sources